TRIBASIC CALCIUM PHOSPHATE

N/A

Manufactured by DNA Labs, Inc.

1,206 FDA adverse event reports analyzed

Last updated: 2026-04-15

About TRIBASIC CALCIUM PHOSPHATE

TRIBASIC CALCIUM PHOSPHATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by DNA Labs, Inc.. The most commonly reported adverse reactions for TRIBASIC CALCIUM PHOSPHATE include DIARRHOEA, PAIN, HEADACHE, FATIGUE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TRIBASIC CALCIUM PHOSPHATE.

Top Adverse Reactions

DIARRHOEA37 reports
PAIN33 reports
HEADACHE31 reports
FATIGUE30 reports
NAUSEA27 reports
ARTHRALGIA26 reports
DIZZINESS26 reports
ASTHENIA21 reports
DYSPEPSIA21 reports
HYPERSENSITIVITY21 reports
PAIN IN EXTREMITY21 reports
GAIT DISTURBANCE20 reports
DYSPNOEA19 reports
DEPRESSION18 reports
DRUG INEFFECTIVE18 reports
MALAISE18 reports
MUSCLE SPASMS18 reports
NECK PAIN18 reports
ABDOMINAL PAIN UPPER17 reports
EYE PAIN17 reports
FEELING ABNORMAL17 reports
FALL16 reports
INSOMNIA16 reports
RASH16 reports
VOMITING16 reports
WEIGHT DECREASED16 reports
ABDOMINAL DISTENSION15 reports
CONSTIPATION15 reports
ERUCTATION15 reports
PRURITUS15 reports
ALOPECIA14 reports
BARRETT^S OESOPHAGUS14 reports
OROPHARYNGEAL DISCOMFORT14 reports
PARAESTHESIA14 reports
PRODUCT DOSE OMISSION ISSUE14 reports
REGURGITATION14 reports
VITAMIN B12 DEFICIENCY14 reports
BLOOD PRESSURE INCREASED13 reports
HYPOAESTHESIA13 reports
PNEUMONIA13 reports
WEIGHT INCREASED13 reports
BALANCE DISORDER12 reports
DEATH12 reports
OFF LABEL USE12 reports
CONFUSIONAL STATE11 reports
DECREASED APPETITE11 reports
FLUSHING11 reports
VISION BLURRED11 reports
BACK PAIN10 reports
CONDITION AGGRAVATED10 reports
MIGRAINE10 reports
MULTIPLE SCLEROSIS RELAPSE10 reports
PRODUCT SUBSTITUTION ISSUE10 reports
TREMOR10 reports
ANXIETY9 reports
PERIPHERAL SWELLING9 reports
SEIZURE9 reports
HOT FLUSH8 reports
INTENTIONAL PRODUCT MISUSE8 reports
NEUROPATHY PERIPHERAL8 reports
PALPITATIONS8 reports
PRODUCT DOSE OMISSION8 reports
URTICARIA8 reports
ABDOMINAL DISCOMFORT7 reports
CHEST PAIN7 reports
CHILLS7 reports
CONTUSION7 reports
COVID 197 reports
DRUG DOSE OMISSION7 reports
HEART RATE INCREASED7 reports
MEMORY IMPAIRMENT7 reports
MOBILITY DECREASED7 reports
MUSCULAR WEAKNESS7 reports
MYALGIA7 reports
NASOPHARYNGITIS7 reports
OROPHARYNGEAL PAIN7 reports
VISUAL IMPAIRMENT7 reports
BLOOD GLUCOSE INCREASED6 reports
BURNING SENSATION6 reports
CHRONIC KIDNEY DISEASE6 reports
DRUG INTOLERANCE6 reports
GASTROINTESTINAL DISORDER6 reports
HALLUCINATION6 reports
ILLNESS6 reports
JOINT SWELLING6 reports
PRODUCT USE ISSUE6 reports
PYREXIA6 reports
SOMNOLENCE6 reports
SPEECH DISORDER6 reports
THERAPY CESSATION6 reports
VERTIGO6 reports
ARTHRITIS5 reports
CATARACT5 reports
COUGH5 reports
DEHYDRATION5 reports
DRUG HYPERSENSITIVITY5 reports
DYSGEUSIA5 reports
DYSPHAGIA5 reports
EPISTAXIS5 reports
FEELING HOT5 reports

Report Outcomes

Out of 514 classified reports for TRIBASIC CALCIUM PHOSPHATE:

Serious 57.8%Non-Serious 42.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female343 (68.7%)
Male156 (31.3%)

Reports by Age

Age 7017 reports
Age 6616 reports
Age 6816 reports
Age 6515 reports
Age 7514 reports
Age 5813 reports
Age 7213 reports
Age 5112 reports
Age 7112 reports
Age 7412 reports
Age 8112 reports
Age 6411 reports
Age 7611 reports
Age 6110 reports
Age 6910 reports
Age 739 reports
Age 829 reports
Age 528 reports
Age 678 reports
Age 477 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with TRIBASIC CALCIUM PHOSPHATE?

This profile reflects 1,206 FDA FAERS reports that mention TRIBASIC CALCIUM PHOSPHATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for TRIBASIC CALCIUM PHOSPHATE?

Frequently reported terms in FAERS include DIARRHOEA, PAIN, HEADACHE, FATIGUE, NAUSEA, ARTHRALGIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures TRIBASIC CALCIUM PHOSPHATE?

Labeling and FAERS entries often list DNA Labs, Inc. in connection with TRIBASIC CALCIUM PHOSPHATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.